Met-Plus-G2 Tablet SR is a sustained-release oral antidiabetic medication combining Glimepiride 2mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake in muscle tissues. The sustained-release formulation ensures gradual drug release, promoting stable plasma concentrations and improved gastrointestinal tolerability. Met-Plus-G2 is prescribed as an adjunct to diet and exercise to achieve optimal glycemic control in patients inadequately controlled by monotherapy or lifestyle modifications alone. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia may occur due to Glimepiride. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Met-Plus-G2 Tablet SR offers a synergistic approach to glycemic management by combining two complementary mechanisms of action, facilitating improved patient adherence through once-daily dosing.